Aarti Pharmalabs Ltd
BSE:543748
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Aarti Pharmalabs Ltd
BSE:543748
|
IN |
|
G
|
Gogo Inc
SWB:G0G
|
US |
|
B
|
Ballard Power Systems Inc
DUS:PO0
|
CA |
Aarti Pharmalabs Ltd
Aarti Pharmalabs Ltd makes ingredients and finished chemical building blocks used in medicines. The company supplies pharmaceutical intermediates and active pharmaceutical ingredients, and it also works on contract development and manufacturing for drug makers. In simple terms, it sits in the middle of the drug supply chain: it helps turn chemistry into the compounds that end up in medicines. Its customers are pharmaceutical companies that need a reliable source of regulated ingredients or a manufacturing partner for specific molecules. Some customers buy standard products, while others pay Aarti Pharmalabs to develop a process and make a molecule to their specifications. The company earns money by selling these products and by charging for development and manufacturing work. What makes the business model different is that it combines ingredient supply with technical know-how. That matters in pharmaceuticals because buyers care about quality, consistency, and the ability to make complex molecules under strict standards. Aarti Pharmalabs is not a drug brand company; it is a behind-the-scenes supplier and manufacturing partner for the pharma industry.
Aarti Pharmalabs Ltd makes ingredients and finished chemical building blocks used in medicines. The company supplies pharmaceutical intermediates and active pharmaceutical ingredients, and it also works on contract development and manufacturing for drug makers. In simple terms, it sits in the middle of the drug supply chain: it helps turn chemistry into the compounds that end up in medicines.
Its customers are pharmaceutical companies that need a reliable source of regulated ingredients or a manufacturing partner for specific molecules. Some customers buy standard products, while others pay Aarti Pharmalabs to develop a process and make a molecule to their specifications. The company earns money by selling these products and by charging for development and manufacturing work.
What makes the business model different is that it combines ingredient supply with technical know-how. That matters in pharmaceuticals because buyers care about quality, consistency, and the ability to make complex molecules under strict standards. Aarti Pharmalabs is not a drug brand company; it is a behind-the-scenes supplier and manufacturing partner for the pharma industry.
Revenue: Stand-alone revenue rose 9% year on year to INR 580 crores in Q4 FY '26, but full-year revenue was only slightly higher at INR 1,798 crores versus INR 1,771 crores in FY '25.
Profitability: EBITDA fell to INR 134 crores in Q4 and INR 406 crores for the year, as inflation, logistics costs, and ramp-up expenses weighed on margins.
CDMO growth: CDMO/CMO hit its highest-ever quarterly revenue of INR 155 crores and grew 32% year on year for the full year; management said it remains the main growth engine.
Xanthine scale-up: Xanthine derivatives also hit a record quarter, contributed 43% of Q4 turnover, and the company said the new capacity can take segment revenue well beyond INR 1,000 crores.
API recovery: API and intermediates stayed under pressure from competition and prior inventory issues, but management expects FY '27 growth and said it should surpass FY '25 levels.
CapEx ramp: The company spent about INR 400 crores in FY '26 and plans a similar amount in FY '27, with more brownfield work ahead and lower capital intensity expected from FY '28 onward.
Outlook: Management kept its medium-term target of 15% to 18% revenue and EBITDA growth over 3 to 4 years, while saying FY '27 timing will depend on customer approvals and project ramp-ups.
